Lv1
68 积分 2022-05-30 加入
D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial
3天前
已完结
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies
16天前
已完结
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
17天前
已完结
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
17天前
已完结
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
17天前
已完结
Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase
18天前
已完结
Sotorasib’s Accelerated Approval
23天前
已完结
Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis
1个月前
已完结
Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
2个月前
已完结
Better prediction of the local concentration–effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development
2个月前
已完结
皖公网安备34019202002308
